瑞他鲁肽 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Extremophile – Organisms capable of living in extreme environments Ombrophobe – Plant adverse to rainfall Osmophile – Organism tolerant osmotic effects from a low water activity Xerocole – Any animal adapted to live in the desert Xerophyte – A plant adapted to a hot dry environment
Muscle fatigue is when muscles that were initially generating a normal amount of force, then experience a declining ability to generate force. It can be a result of vigorous exercise, but abnormal fatigue may be caused by barriers to or interference with the different stages of muscle contraction. There are two main causes of muscle fatigue: the limitations of a nerve's ability to generate a sustained signal (neural fatigue); and the reduced ability of the muscle fiber to contract (metabolic fatigue). Muscle fatigue is not the same as muscle weakness, though weakness is an initial symptom. Despite a normal amount of force being generated at the start of activity, once muscle fatigue has set in and progressively worsens, if the individual persists in the exercise they will eventually lose their hand grip, or become unable to lift or push with their arms or legs, or become unable to maintain an isometric position (such as plank). Other symptoms may accompany such as myalgia (muscle pain), shortness of breath, fasciculations (muscle twitching), myokymia (muscle trembling), and muscle cramps during exercise; muscle soreness may occur afterwards. An inappropriate rapid heart rate response to exercise may be seen, such as in the metabolic myopathy of McArdle disease (GSD-V), where the heart tries to compensate for the deficit of ATP in the skeletal muscle cells (metabolic fatigue) by increasing heart rate to maximize delivery of oxygen and blood borne fuels to the muscles for oxidative phosphorylation.
The heart is an organ located in the thoracic cavity between the lungs and slightly to the left. It is surrounded by the pericardium, which holds it in place in the mediastinum and serves to protect it from blunt trauma, infection and help lubricate the movement of the heart via pericardial fluid. The heart works by pumping blood around the body allowing oxygen, nutrients, waste, hormones and white blood cells to be transported.
=== No development reported === AF-130 – purinergic P2X3 receptor antagonist – migraine [40] B-244 (AOB-101; AOB-102; AOB-103; AOB-201; AOB-202; AOB-203; B244; nitrosomonas eutropha D23) – bacteria replacement – migraine [41] Carabersat (SB-204269) – undefined mechanism of action (anticonvulsant) – migraine [42] CLE-500 – undefined mechanism of action – cluster headache [43] CT-044 analogues - CERSCI Therapeutics – reactive oxygen species (ROS) inhibitor – migraine [44] Cyclobenzaprine extended release (Amrix; Bonelax; EUR-1002) – tricyclic antidepressant (non-selective monoamine reuptake inhibitor and receptor modulator and other actions) – migraine [45] Donepezil (Allydone; Aricept; E-2020; E-2022; Eranz) – acetylcholinesterase inhibitor – migraine [46] Donitriptan mesilate (F-12640) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [47] Estetrol (E4; Donesta) – estrogen (estrogen receptor agonist) – migraine [48] Filorexant (MK-6096) – orexin OX1 and OX2 receptor antagonist – migraine [49] Flunarizine (XEN-007) – calcium channel blocker, non-selective monoamine receptor modulator, other actions – migraine [50] Ibudilast (AV-411; Eyevinal; Ibinal; KC-404; Ketas; MN-166; Pinatos) – phosphodiesterase PDE4 inhibitor – headache [51] IPX-232 – undefined mechanism of action – migraine [52] Ketamine hydrochloride intranasal – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – cluster headache [53] Ondansetron/rizatriptan – oral transmucosal film (rizatriptan/ondansetron; MSRX-202) – combination of ondansetron (serotonin 5-HT3 receptor antagonist and antiemetic) and rizatriptan (triptan) [54] Oxytocin (TI-001; TI-114; TNX-1900; TNX-2900) – oxytocin receptor agonist – headache [55] Piroxicam betadex (β-cyclodextrin piroxicam; Brexecam; Brexidol; Brexin; Brexine; Brexinil; CHF 1194; Cicladol; Cycladol; Flogene; piroxicam β-cyclodextrin) – COX inhibitor/NSAID – migraine, tension-type headache [56] Psilocybin (low-dose psilocybin; BPL-PSILO) – non-selective serotonin receptor agonist and psychedelic hallucinogen – headache [57] Psilocybin (MYCO-001; MYCO-003) – non-selective serotonin receptor agonist and psychedelic hallucinogen – headache [58] Psilocybin (SYNP-101; synthetic psilocybin) – non-selective serotonin receptor agonist and psychedelic hallucinogen – cluster headache, migraine [59] Relutrigine (PRAX-562) – sodium channel blocker – headache [60] Research programme: calcitonin gene-related peptide receptor antagonists - Merck (CGRP receptor antagonists; Imidazoazepanes; MK-2918; MK-8825) – calcitonin gene-related peptide receptor (CGRPR) antagonists [61] Research programme: GPCR modulators - Nxera Pharma – various actions [62] Research programme: migraine and pain therapeutics - NeurAxon – various actions – migraine [63] Research programme: pain and migraine therapy - OptiNose (OPT-1005) – undefined mechanism of action – migraine [64] Rizatriptan intranasal – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [65] Rizatriptan oral film – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [66] Salubrin (PH80; PH-80; ORG-39479) – vomeropherine – migraine [67] [68] Sumatriptan (Imigran Nasal Spray; Imitrex Nasal Spray) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – menstrual migraine [69] Sumatriptan transmucosal (Omexa) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [70] Zucapsaicin (cis-capsaicin; Civamide; Civanex; Dolorac; Neuroderm; Zuacta) – transient receptor potential cation channel subfamily V member 1 (TRPV1) agonist – cluster headache, migraine [71]
thermal abuse, e.g. poor cooling or external fire, electrical abuse, e.g. overcharge or external short circuit, mechanical abuse, e.g. penetration or crash, or internal short circuit, e.g. due to manufacturing flaws or aging. Because of these risks, testing standards are more stringent than those for acid-electrolyte batteries, requiring both a broader range of test conditions and additional battery-specific tests, and there are shipping limitations imposed by safety regulators. There have been battery-related recalls by some companies, including the 2016 Samsung Galaxy Note 7 recall for battery fires. Lithium-ion batteries have a flammable liquid electrolyte. A faulty battery can cause a serious fire. Faulty chargers can affect the safety of the battery because they can destroy the battery's protection circuit. While charging at temperatures below 0 °C, the negative electrode of the cells gets plated with pure lithium, which can compromise the safety of the whole pack. Short-circuiting a battery will cause the cell to overheat and possibly to catch fire. Smoke from thermal runaway in a Li-ion battery is both flammable and toxic. Batteries are tested according to the UL 9540A fire standard, and the TS-800 standard also tests fire propagation from one battery container to adjacent containers.
Sources: en.wikipedia.org
During later Crusades, deals were made with the Venetian fleet and merchants to keep soldiers supplied. However, their food supplies were consistently low, to the point that in several battles crusaders would "stop fighting and start eating" upon discovering food in the camps of Muslim armies. During the Third Crusade, an observer noted several kitchens in Saladin's camp with nine large cauldrons each. The armies of the Mongol Empire only had whatever food or livestock they brought from home, and relied on whatever food they could pillage. Mongol soldiers were supplied by their own households and Mongol armies brought along herds of cows and sheep with them on campaign. When livestock was unavailable, they would subsist on rations such as cured meat, dried milk curd, and mare's milk, both fresh and fermented into kumis, as well as hunt local game. According to Marco Polo, a Mongol cavalryman could go ten days without having to cook, and in such situations would rely on ten pounds (4.5 kg) of dried milk curd, two liters of kumis, and a quantity of cured meat. In the Ottoman Empire, janissaries were some of the most well-fed soldiers of the era, with access to a variety of foods. Their diet largely consisted of freshly baked bread and biscuits when bread was unavailable, as well as a daily meat ration of about 200 grams of lamb or mutton, coffee, rice, and bulgur. Biscuits were of particular importance. An observer noted around 105 ovens in Istanbul dedicated solely to baking for military purposes.
An ectomycorrhiza (from Ancient Greek ἐκτός (ektós) 'outside', μύκης (múkēs) 'fungus' and ῥίζα (rhíza) 'root'; abbreviated EcM; pl. ectomycorrhizae or ectomycorrhizas) is a form of symbiotic relationship that occurs between a fungal symbiont, or mycobiont, and the roots of various plant species. The mycobiont is often from the division Basidiomycota and Ascomycota, and more rarely from the Zygomycota. Ectomycorrhizae form on the roots of around 2% of plant species, usually woody plants, including species from the birch, dipterocarp, myrtle, beech, willow, pine and rose families. Research on ectomycorrhizae is increasingly important in areas such as ecosystem management and restoration, forestry, and agriculture. Unlike other mycorrhizal relationships, such as arbuscular mycorrhiza and ericoid mycorrhiza, ectomycorrhizal fungi do not penetrate their host's cell wall. Instead they form an entirely intercellular interfaces known as the Hartig net, consisting of highly branched hyphae forming a latticework between epidermal and cortical root cells. Ectomycorrhizas are further differentiated from other mycorrhizas by the formation of a dense hyphal sheath, known as the mantle, surrounding the root surface. This sheathing mantle can be up to 40 μm thick, with hyphae extending up to several centimeters into the surrounding soil. The hyphal network helps the plant to take up nutrients including water and minerals, often helping the host plant to survive adverse conditions. In exchange, the fungal symbiont is provided with access to carbohydrates.
Members of palais and fadas may be targets of recruitment by militant groups such as Boko Haram and violent opposition politicians. Samari often become politically involved through fadas. As political candidates must target the large demographic of youths to be successful, they stop at fadas during campaigns. Some fadas serve as headquarters for election campaigns, displaying the banners of their political parties. Parties often hire fadantchés, as well as members of women's associations, as brokers for their campaigns. Fadantchés may use networks of fadas to mobilize others to vote, which increases the recognition of their own fadas. Candidates also receive fadantchés' phone numbers to ensure they show up to vote. When political candidates visit fadas, they mostly speak about promises to their voters, and they may give gifts such as tea to buy their votes. This practice is satirized in the music video "Fada Flow" by Kaidan Gaskia 2, which depicts a vote-buying politician being rejected by a fada. After an election is complete, fadantchés often rally for the opposition. Although many fadas explicitly support political parties, many others are apolitical, and they may have a rule that members may not accept payment for votes.
Treatments for ATTR-related neuropathy include TTR-specific oligonucleotides in the form of small interfering RNA (patisiran) or antisense inotersen, the former having recently received FDA approval. Research into treatments for ATTR amyloidosis have compared liver transplantation, oral drugs that stabilize the misfolding protein (including tafamidis and diflunisal), and newer therapeutic agents still being investigated (including patisiran). Based on available research, liver transplant remains the most effective treatment option for advanced ATTR amyloidosis, protein stabilizing drugs may slow disease progression but were insufficient to justify delay of liver transplant, and newer agents such as patisiran require additional studies. Peptide synthesis Proteinopathy
Sources: en.wikipedia.org
Lemmon, well aware of Quaalude's public image problems, used advertisements in medical journals to urge physicians "not to permit the abuses of illegal users to deprive a legitimate patient of the drug". Lemmon also marketed a small quantity under another name, Mequin, so doctors could prescribe the drug without the negative connotations. The rights to Quaalude were held by the JB Roerig & Company division of Pfizer, before the drug was discontinued in the United States in 1985, mainly due to its psychological addictiveness, widespread abuse, and illegal recreational use. A 2024 Hungarian investigative documentary reported on large-scale production and sales of the drug by the Hungarian People's Republic to the United States in the 1970s and 1980s. It asserts that a Hungarian state-owned company utilized connections to Colombian drug cartels to facilitate the sale of extraordinary amounts to the United States.
Complete androgen insensitivity syndrome (CAIS) is an AIS condition that results in the complete inability of the cell to respond to androgens. As such, the insensitivity to androgens is only clinically significant when it occurs in individuals who are exposed to significant amounts of testosterone at some point in their lives. The unresponsiveness of the cell to the presence of androgenic hormones prevents the masculinization of male genitalia in the developing fetus, as well as the development of male secondary sexual characteristics at puberty, but does allow, without significant impairment, female genital and sexual development in those with the condition. All human fetuses begin fetal development looking similar, with both the Müllerian duct system (female) and the Wolffian duct system (male) developing. Sex differentiation begins with the gonads, which in XX individuals become ovaries, and in XY individuals (including those with CAIS) typically become testicles due to the presence of the Y chromosome. It is at the seventh week of gestation that the bodies of non-CAIS individuals with the XY karyotype begin their masculinization: i.e., the Wolffian duct system is promoted and the Müllerian duct system is suppressed (the reverse happens with typically developing females). This process is triggered by androgens produced by the testicles.
Fast protein liquid chromatography (FPLC), is a form of liquid chromatography that is often used to analyze or purify mixtures of proteins. As in other forms of chromatography, separation is possible because the different components of a mixture have different affinities for two materials, a moving fluid (the "mobile phase") and a porous solid (the stationary phase). In FPLC the mobile phase is an aqueous solution, or "buffer". The buffer flow rate is controlled by a positive-displacement pump and is normally kept constant, while the composition of the buffer can be varied by drawing fluids in different proportions from two or more external reservoirs. The stationary phase is a resin composed of beads, usually of cross-linked agarose, packed into a cylindrical glass or plastic column. FPLC resins are available in a wide range of bead sizes and surface ligands depending on the application.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.